Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target
Cancers · 17.02.2023 · 15 (4) · 1287
DOI: 10.3390/cancers15041287 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.02.2023. Verfasst von Guoqiang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Nature Science Foundation of China, National Nature Science Foundation of China.
Abstract (Originalsprache)
Prostate cancer (PCa) is a highly heterogeneous disease driven by gene alterations and microenvironmental influences. Not only enhanced serum IGF-1 but also the activation of IGF-1R and its downstream signaling components has been increasingly recognized to have a vital driving role in the development of PCa. A better understanding of IGF-1/IGF-1R activity and regulation has therefore emerged as an important subject of PCa research. IGF-1/IGF-1R signaling affects diverse biological processes in cancer cells, including promoting survival and renewal, inducing migration and spread, and promoting resistance to radiation and castration. Consequently, inhibitory reagents targeting IGF-1/IGF-1R have been developed to limit cancer development. Multiple agents targeting IGF-1/IGF-1R signaling have shown effects against tumor growth in tumor xenograft models, but further verification of their effectiveness in PCa patients in clinical trials is still needed. Combining androgen deprivation therapy or cytotoxic chemotherapeutics with IGF-1R antagonists based on reliable predictive biomarkers and developing and applying novel agents may provide more desirable outcomes. This review will summarize the contribution of IGF-1 signaling to the development of PCa and highlight the relevance of this signaling axis in potential strategies for cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
ORCID-Profile: Feng Pan
Förderung
- the National Nature Science Foundation of China
- National Nature Science Foundation of China
Zitieren
APA
Liu, G., Zhu, M., Zhang, M., & Pan, F. (2023). Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target. Cancers, 15(4), 1287. https://doi.org/10.3390/cancers15041287
Vancouver
Liu G, Zhu M, Zhang M, Pan F. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target. Cancers. 2023;15(4):1287. doi:10.3390/cancers15041287
BibTeX
@article{Liu2023,
author = {Liu, Guoqiang and Zhu, Minggang and Zhang, Mingrui and Pan, Feng},
title = {Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target},
journal = {Cancers},
year = {2023},
volume = {15},
number = {4},
pages = {1287},
doi = {10.3390/cancers15041287}
}
EUVIMED